Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis

Journal of Infectious Diseases

Volumn 178, Issue 2, 1998, Pages 531-534

  Erice, Alejo ^a,b   Borrell, Nuria ^a   Li, Wuyi ^a   Miller, Wesley J ^a   Balfour Jr , Henry H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE ISOLATION; GENE MUTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS GENE;

EID: 0031872795     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517467     Document Type: Article

References (16)

1. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990;12(suppl 7):S776-92.
2. Meyers JD, Reed E, Shepp DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic bone marrow transplantation. N Engl J Med 1988;318:70-5.
3. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324:1005-11,
4. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-2.
5. Talarico CL, Stanat SC, Biron KK. Evidence that HCMV-encoded UL97 contributes to the phosphorylation of acyclovir in HCMV-infected cells [abstract H65]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando). Washington, DC: American Society for Microbiology, 1994:206.
6. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr, Jordan C. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
7. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 1991;163: 716-9.
8. Chou S, Erice A, Jordan C, et al. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995;171: 576-83.
9. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
10. Erice A, Gil-Roda C, Pérez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175: 1087-92.
11. Drobyski WR, Knox KK, Carrigan DR, Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 1991;52:155-7.
12. Reusser P, Cordonnier C, Einsele H, et al. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant 1996;17:813-7.
13. Slavin M, Bindra R, Cleaves C, Pettinger M, Bowden R. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993;37:1360-3.
14. Cole NL, Balfour HH Jr. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-61.
15. Drew WL, Andersen R, Lang W, Miner RC, Davis G, Lalezari J. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J Acquir Immune Defic Syndr 1995;8:289-91.
16. Boivin G, Erice A, Crane DD, Dunn DL, Balfour HH Jr. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis. J Infect Dis 1993;168:332-5.